Molecular pathology of myelodysplastic syndromes: Biology of medullary stromal and hematopoietic cells (Review)

Molecular Medicine Reports

Volumn 4, Issue 4, 2011, Pages 591-596

  Kitagawa, Masanobu ^a   Kurata, Morito ^a   Yamamoto, Kouhei ^a   Abe, Shinya ^a   Suzuki, Shiho ^a   Umeda, Shigeaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Hematopoietic cell; Myelodysplastic syndromes; Stromal cell

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; GELATINASE A; GELATINASE B; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; JANUS KINASE 2; OSTEONECTIN; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLACKFAN DIAMOND ANEMIA; BONE MARROW; CANCER GROWTH; CELL RENEWAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE MODEL; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HAPLOINSUFFICIENCY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; INTERMETHOD COMPARISON; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RPS14 GENE; SBDS GENE; SHWACHMAN SYNDROME; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL NICHE; STROMA CELL; TET2 GENE; UNIPARENTAL DISOMY;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CYTOKINES; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CYTOKINE; STROMAL CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957646507     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.493     Document Type: Review

References (63)

1. Raza A, Preisler HD, Mayers GL and Bankert R: Rapid enumeration of S-phase cells by means of monoclonal antibodies. N Engl J Med 310: 991, 1984. (Pubitemid 14173247)
2. Raza A, Maheshwari Y and Preisler HD: Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 69: 1647-1653, 1987. (Pubitemid 17091620)
3. Kitagawa M, Kamiyama R and Kasuga T: Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. Hum Pathol 24: 359-363, 1992. (Pubitemid 23127250)
4. Raza A, Gezer S, Mundle S, et al: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86: 268-276, 1995.
5. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R and Hirokawa K: Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11: 2049-2054, 1997. (Pubitemid 28043688)
6. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K and Kamiyama R: Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 12: 486-492, 1998. (Pubitemid 28197571)
7. Kitagawa M, Takahashi M, Yamaguchi S, Inoue M, Ogawa S, Hirokawa K and Kamiyama R: Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Leukemia 13: 699-703, 1999. (Pubitemid 29243619)
8. Raza A, Gregory SA and Preisler HD: The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 20: 881-890, 1996.
9. Mundle SD, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM, Mativi BY, Shetty VT, Venugopal P, Gregory SA and Raza A: Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 60: 36-47, 1999. (Pubitemid 28565850)
10. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P and Fontenay-Roupie M: In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99: 1594-1601, 2002.
11. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F and Zauli G: Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166: 557-563, 2005. (Pubitemid 40189051)
12. Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R, Hirokawa K and Kitagawa M: Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leukemia Res 27: 583-591, 2003. (Pubitemid 36398093)
13. Raza A, Cruz R, Latif T, Mukherjee S and Galili N: The biology of myelodysplastic syndromes: unity despite heterogeneity. Hemato Rep 2: 28-31, 2010.
14. Horikawa K, Nakakuma H, Kawaguchi T, Iwamoto N, Nagakura S, Kagimoto T and Takatsuki K: Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 90: 2716-2722, 1997. (Pubitemid 27413481)
15. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann Gibson B, Frutiger Y, Grogan TM and List AF: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukaemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427-1434, 2001. (Pubitemid 32183769)
16. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H and Albitar M: Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol 118: 151-156, 2002. (Pubitemid 34779531)
17. Keith T, Araki Y, Ohyagi M, Hasegawa M, Yamamoto K, Kurata M, Nakagawa Y, Suzuki K and Kitagawa M: Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 137: 206-215, 2007. (Pubitemid 46537630)
18. Iwata M, Pillai M, Ramakrishnan A, Hackman RC, Deeg HJ, Opdenakker G and Torok-Storb B: Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 109: 85-92, 2007. (Pubitemid 46053047)
19. Travaglino E, Benatti C, Malcovati L, Della Porta MG, Gallì A, Sonetti E, Rosti V, Cazzola M and Invernizzi R: Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukemias and myelodysplastic syndromes. Eur J Haematol 80: 216-226, 2008. (Pubitemid 351253461)
20. Raaijmakers MH, Mukherjee S, Guo S, et al: Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464: 852-857, 2010.
21. Greenberg P, Cox C, LeBeau MM, et al: International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088, 1997. (Pubitemid 27132124)
22. Olney JH and Le Beau MM: The cytogenetics of myelodysplastic syndromes. Best practice and research. Clin Haematol 14: 479-495, 2001.
23. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukaemia: results from Cancer and Leukemia Study Group B (CALGB 8461). Blood 100: 4325-4336, 2002. (Pubitemid 35429670)
24. Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Lazzarino M and Bernasconi C: Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19: 1424-1431, 2005. (Pubitemid 41136337)
25. Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Dambruoso I, Lazzarino M and Bernasconi C: World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol 137: 193-205, 2006. (Pubitemid 46537628)
26. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of karyotype in MDS and correlations with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007. (Pubitemid 351377805)
27. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL and Sokal G: Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251: 437-438, 1974.
28. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M and Aul C: Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18: 113-119, 2004. (Pubitemid 38159446)
29. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R and Jacobsen SE: Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96: 2012-2021, 2000.
30. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR and Golub TR: Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451: 335-339, 2008.
31. Draptchinskaia N, Gustavsson P, Andersson B, et al: The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nature Gen 21: 169-175, 1999. (Pubitemid 29070361)
32. Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson R, Lees JA and Hopkins N: Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2: E139, 2004.
33. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al: Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nature Med 16: 49-58, 2010.
34. Barlow JL, Drynan LF, Hewett DR, et al: A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nature Med 16: 59-66, 2010.
35. Jädersten M and Hellström-Lindberg E: New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp Cell Res 316: 1390-1396, 2010.
36. Pellagatti A, Jadersten M, Forsblom AM, et al: Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndromepatients. Proc Natl Acad Sci USA 104: 11406-11411, 2007. (Pubitemid 47175153)
37. Framson PE and Sage EH: SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92: 679-690, 2004.
38. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434: 1144-1148, 2005. (Pubitemid 40663494)
39. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270, 2006.
40. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468, 2007. (Pubitemid 46193073)
41. Szpurka H, Tiu R, Murugesan G, Aboudola S, His ED, Theil KS, Sekeres MA and Maciejewski JP: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108: 2173-2181, 2006. (Pubitemid 44497497)
42. Ingram W, Lea NC, Cervera J, et al: The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 20: 1319-1321, 2006. (Pubitemid 43905846)
43. Abdel-Wahab O, Mullally A, Hedvat C, et al: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114: 144-147, 2009.
44. Delhommeau F, Dupont, S, della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301, 2009.
45. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA and Maciejewski JP: Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113: 6403-6410, 2009.
46. Langemeijer SM, Kuiper RP, Berends M, et al: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet 41: 838-842, 2009.
47. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U and Mufti GJ: Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 27: 4002-4006, 2009.
48. Kosmider O, Gelsi-Boyer V, Cheok M, et al: TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114: 3285-3291, 2009.
49. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935, 2009.
50. Makishima H, Cazzolli H, Szpurka H, et al: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 27: 6109-6116, 2009.
51. Gelsi-Boyer V, Trouplin V, Adelaide J, et al: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145: 788-800, 2009.
52. Boultwood J, Perry J, Pellagatti A, et al: Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24: 1062-1065, 2010.
53. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS and Maciejewski JP: Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111: 1534-1542, 2008. (Pubitemid 351213443)
54. Mohamedali A, Gäken J, Twine NA, et al: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110: 3365-3373, 2007. (Pubitemid 350106331)
55. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, et al: Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23: 1605-1613, 2009.
56. Andreakos E, Foxwell B and Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 202: 250-265, 2004.
57. Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol 21: 335-276, 2003.
58. Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nature Rev Cancer 9: 57-63, 2009.
59. Kuninaka N, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S, Arai A, Nakagawa Y, Suzuki K and Kitagawa M: Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp Mol Pathol 88: 293-298, 2010.
60. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, Ni H, Saunthararajah Y and Nucifora G: EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 114: 713-719, 2004. (Pubitemid 39582822)
61. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K and Pandolfi PP: Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437: 147-153, 2005. (Pubitemid 41613442)
62. Lin YW, Slape C, Zhang Z and Aplan PD: NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukaemia. Blood 106: 287-295, 2005. (Pubitemid 40967204)
63. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T and Kitamura T: AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111: 4297-4308, 2008.